MeiraGTx Holdings plc
MGTXNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $81.4M | $33.3M | $14.0M | $15.9M | $37.7M | $15.6M |
| Operating income | −$106.0M | −$164.2M | −$137.1M | −$116.4M | −$72.8M | −$62.6M |
| Net income | −$114.2M | −$147.8M | −$84.0M | −$129.6M | −$79.6M | −$58.0M |
| Total assets | $244.4M | $269.8M | $326.7M | $318.2M | $320.2M | $363.7M |
| Total liabilities | $250.2M | $201.9M | $188.6M | $200.5M | $134.8M | $125.1M |
| Equity | −$5.8M | $67.8M | $138.2M | $117.7M | $185.4M | $238.6M |
| EPS (diluted) | $-1.42 | $-2.12 | $-1.49 | $-2.87 | $-1.80 | $-1.54 |
| Shares out. | 78.9M | 64.2M | 48.7M | 44.7M | 44.3M | 36.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −130.2%
- Net margin
- −140.3%
- Return on equity
- 1971.4%
- Return on assets
- −46.7%
- Return on capital (ROCE)
- −86.9%
- Liabilities / assets
- 102.4%
- Debt / equity
- —
- Book value / share
- $-0.07
- Revenue growth (YoY)
- 144.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -14.65distress
- Accruals / assets
- −27.8%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Active Not Recruitingreadout ~2026-07Safety of a Single Administration of AAV2hAQP1, an Adeno-Associated Viral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in People With Irradiation-Induced Parotid Salivary Hypofunction
- Phase 2Recruitingreadout ~2026-12A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
- Phase 1/2Active Not Recruitingreadout ~2029-10Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease
- Phase 2Enrolling By Invitationreadout ~2032-02Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Adage Capital Management, L.P.Passive (13G)May 13, 2026
- Perceptive Advisors LlcActivist (13D)Apr 24, 2026
- Prosight Management, LpPassive (13G)Feb 13, 2026
- Rubric Capital Management LpPassive (13G)Feb 13, 2026
- Adena Estate Inc.Passive (13G)Feb 9, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 5.4M | 10.3 | -5.1% |
| Apr 30, 2026 | 5.7M | 4.3 | +23.9% |
| Apr 15, 2026 | 4.6M | 5.8 | -10.2% |
| Mar 31, 2026 | 5.2M | 8.0 | -2.8% |
| Mar 13, 2026 | 5.3M | 12.0 | +4.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 14, 2026
- Entered a material agreementApr 24, 2026
- Entered a material agreementApr 16, 2026
- Entered a material agreement · Terminated a material agreement · Completed an acquisition or disposition · Regulation FD disclosure · Other material eventApr 16, 2026
- Regulation FD disclosure · Other material eventApr 16, 2026
- Entered a material agreement · Results of operations · New financial obligationMar 26, 2026
- Entered a material agreementJan 2, 2026
- Results of operationsNov 13, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.